OXBT gapped upward on Friday and held over the 50dma. While the stock pulled back from its highs on the day, volume was the highest in over a month. Today we will be watching the stock to see what it does, keeping an eye on the heavy resistance at $2.20. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts.php Let us hear your thoughts below:
Oregon-based Powin Corp. recently announced that sales for the first quarter of 2011, ended March 31, totaled $10.95 million, up 11 percent from sales of $9.86 million in the same period of last year. The company, a direct manufacturer of outdoor cookware products, gun safes, fitness and recreational equipment, truck parts, plastic products, renewable energy products and furniture, posted net income of $31,331 for the first quarter of 2011. Powin’s gross profits in the first quarter of 2011 totaled $1.54 million, up almost 12 percent from last year. Gross profits equal 14 percent of the company’s net revenues. Ronald Horne,…
Today before the opening bell, Cono Italiano, Inc., the exclusive license holder of the North American Distribution and Manufacturing rights for "Pizza Cono", a cone-shaped "on-the-go" pizza food product, announced it will soon offer the Pizza Cono as a microwavable product, in addition to its existing variations. Cono Italiano, Inc. and their licensor Spuntibreak.s.r.l., Pizza Hands, inventor of Pizza Cono in Milan Italy, will offer an individual cone available in six flavors that can be easily prepared in a new microwaveable box. Cono Italiano, Inc. and RJM Foods, a food distributor for Cono Italiano, Inc., will be importing the product…
Ziopharm Oncology Inc., a biopharmaceutical company focused on the development and commercialization of cancer therapeutics, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to commence a clinical study of the company’s therapeutic candidate for patients with melanoma. Ad-RTS-IL-12 (INXN 2001/1001) is a novel DNA-based therapeutic candidate. If the IND is approved, the phase I clinical study will be conducted to evaluate the safety of, and the immunological and biological effects of, the drug. Ad-RTS-IL12 is the second clinical oncology product candidate from the Ziopharm/Intrexon Corp. exclusive, synthetic biology channel partnership. "Cancer is…
Juhl Wind Inc., a leader in community-based wind power development in the United States and Canada, Friday announced its results for the first quarter of 2011, marking the company’s first positive operating income in its operating history. Dan Juhl, chairman and CEO of Juhl, praised the company’s performance and its operational success. "We are obviously, very pleased to file our 10Q for the first quarter of 2011 where we accomplished so much and delivered such solid financial results," Juhl stated in the press release. "As we have been reporting to the market, the first part of this year saw us…
On Friday, BEFUT International Co., Ltd. announced their financial results for the third quarter of fiscal 2011 and nine months ended March 31, 2011. Revenue for the third quarter ended March 31, 2011 was $9.4 million, compared to $6.7 million for the third quarter ended March 31, 2010. Gross profit was $2.5 million for the three months ended March 31, 2011. This is in comparison to $1.7 million for the three months ended March 31, 2010. Operating income was $1.4 million for the three months ended March 31, 2011, compared to $1.0 million for the three months ended March 31,…
Dynasty Limousine Inc., a full service Luxury Transportation and Limousine firm covering the southeast United States, has just released first quarter 2011 financial results. The period was the best first quarter since inception with revenues up 39% over Q1 2010, and a net operating margin of 31%. Additional increases were realized in several key areas disclosed in the full report. "2010 was a great growth year for Dynasty and this year is starting off in a very positive direction," said Pierce Fleming, Dynasty Limousine's vice president and chief financial officer. "Demand for our services is at an all time high…
Prime Star Group, Inc. recently announced the formation of Gourmet Fusion Foods as an extension of its Gourmet Fusion Seafood, Inc. operation. Gourmet Fusion Foods is set to serve up a line of kosher-vegan sliders. A small bun or biscuit-like sandwich a few inches across, a ‘slider’ is a favorite for parties and other gatherings. Sliders were first marketed by fast food chain White Castle as “Slyder™”, making the more generic term used by Prime Star easily recognizable to potential customers. Prime Star’s announcement underscores its entry into three potentially lucrative markets: sliders, kosher, and vegan. One research company, NPD…
Advanced Voice Recognition Systems, Inc. is a software development company headquartered in Scottsdale, Arizona, with an office in Mitchell, South Dakota. The company first introduced its speech recognition software and related firmware in 1994 at an industry trade show. Leveraging its portfolio of patents and patent-pending applications, Advanced Voice Recognition Systems intends to attempt to interest other companies in entering into license agreements or other strategic relationships, enforcing and defending its patents through infringement and interference proceedings, as appropriate. Speech recognition technology allows the conversion of speech into written text. Advanced Voice Recognition Systems’ technology focuses on improving speech recognition…
Pro-Pharmaceuticals, Inc., a developmental stage company that engages in the discovery and development of therapeutics for cancer and other diseases, has recently released its financial results for the first quarter of 2011, which ended March 31, 2011. These results will be included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the SEC. “This is an exciting new era for our company as we advance our galectin protein science into two indications with tremendous unmet medical needs. We are collaborating with The Ludwig Institute of Cancer Research in Brussels to expand the application of our galectin…
